Winter Newsletter
August 2001, Number 10
EDITORIAL.
What a week this has been for people like us! First, the Report
of the Royal Commission on Genetic Modification was released at
the end of July. The 1,500 page report which cost $6,000,000 and
took 14 months to be released received 10,000 submissions, which
indicated the intense interest that the NZ public had in this
subject. There were 49 recommendations, one of which was that an
Ethics Council be established. It seems that no one is against
medical research done in the laboratory but we will have to wait
another three months until the end of November before the
Government decides which recommendations it wants to adopt.
In America, President Bush has to make his most difficult
political decision since he was elected. He has to decide
whether his Government will fund research on embryonic stem cells
derived from human embryos, which could lead to cures for retinal
diseases. America's best research scientists work with Federal
funding and in the meantime all FDA funding for this type of
research has been put on hold. After he has made his decision,
Congress then has to approve which way to go and it is uncertain
as to which way they will vote, no matter what Bush decides, as
the Congress is very evenly split numbers wise.
As I write this the "Catching the Knowledge Wave" conference has
just concluded in this country. Professor Robert Lord Winston,
who fronted the two fascinating TV series "The Human Body" and
"Super Human", stressed the need for more support for tertiary
students and the need for more support for scientists in New
Zealand to do basic scientific research.
All of these things will make a difference one way or another in
due course to people with retinal degenerations and it seems that
we will have to patiently wait even longer for the powers that
be to make up their minds what to do.
Meantime the "No Nonsense Eye Sense" Expo will be held in
Auckland on the 22nd September and our Annual General Meeting is
to be held in Wellington on World Retina Day, 29th September.
This issue features New Zealand eye research and Cataracts, which
affect many of our members at some stage. We salute Erik
Weihenmeyer, the first blind man to conquer Mount Everest, the
world's highest peak, and a man with a retinal disorder like
ourselves. Martine Abel, one of Retina's peer supporters, writes
of her loss of colour vision and Dunedin member Helen Adams
publishes her first book. Retina President Tony Haas in his last
letter of his first two year term, looks ahead to what he sees
might be the future for the Society.
June Ombler
207 Forbury Road, St Clair, Dunedin
Phone: (03) 455 8813
Email: jombler@xtra.co.nz
FROM THE PRESIDENT's DESK
By Anthony Haas
Looking ahead
Planning is underway, facilitated by the Wellington branch of
Retina New Zealand, to do more at the Annual General Meeting than
review the society's work programme on peer support, public
education, research and blindness prevention and awareness. The
AGM could build on the success of the "Reaching Out" theme when
the AGM was last in Wellington to reach out to professionals and
other people who can influence the policies of concern to the
voluntary consumer society.
Insufficient progress has been made on designing policies to
address the challenge of increased numbers of New Zealanders
being affected by Age-related Macular Degeneration. The Ministry
of Health's policy development work could take up the issue
through a number of channels:
* in its studies of policies for the ageing society
* in the implementation of the NZ Disability strategy
* in disability committees and boards of District Health Boards.
Retina New Zealand and the RNZFB Blindness Awareness and
Prevention Unit (BAP) could assess whether this is one of the
issues they could each progress in partnership. It could assist
if specialists reviewed such strategies for blindness awareness
and prevention - for example to assess if the statistics on which
policy cases are built can be mobilised. The partnership between
the Blindness Awareness and Prevention Unit and Retina New
Zealand - reflected perhaps in BAP's strategic plan as well as
project cooperation such as the 22nd September Retina Week Eye
Expo, is also ripe for management, planning and development so
that this society's and other interests can be advanced by BAP's
work.
Retina New Zealand, committed to strategies of coping and hoping,
should give appropriate attention to which scientific and medical
issues it wants to advance. The AGM has been asked to consider
policies on genetic modification. There are also policy choices
of a medical and ethical nature to be acknowledged for stem cell
research. There is the question as to whether diabetic
retinopathy, and the concerns of the Diabetes Association, the
needs of people with glaucoma and rare eye diseases need more
attention by Retina New Zealand or those with whom it could work.
The society might want to widen its international sources of
information - the US Foundation Fighting Blindness and the
Lighthouse are two American connections that may respond if asked
to deepen relations.
Retina New Zealand's membership is less than the number of New
Zealanders who have retinal dystrophies - a reaching out
programme at the AGM to Wellingtonians in the policy and
communications process could give new impetus to what should be
a continuing reaching out programme from the branches and active
members.
DONATIONS TO RETINA NEW ZEALAND INC.
From Kaye Newton, Retina NZ Treasurer
At last our society has received approval from the Inland Revenue
Department as a charitable organisation from 1st April 2001.
This means that any donations you make to the society which are
over $5.00 can be claimed as an income tax rebate. You can claim
one third of the donation as a rebate up to a maximum rebate of
$500.00 (or $1,500.00 worth of donations). Please keep your
receipt as proof of the donation if you want to claim the rebate.
RESEARCH
REVIEW OF VISION RESTORED IN A CANINE MODEL OF CHILDHOOD BLINDNESS
By June Ombler
In our last newsletter (No.9, May 2001) we featured an article
on Vision restored in a canine model of childhood blindness.
This began - "In one of the single most important advances in the
history of retinal degeneration research, a group of
Foundation-supported scientists used gene therapy to restore
vision in a canine model of severe childhood blindness, known
clinically as Leber Congenital Amaurosis (LCA). This finding,
published in the May (2001) issue of Nature Genetics, represents
the first time researchers successfully restored vision in a
large animal model of retinal degeneration".
In our November 1997 newsletter I said in my President's letter
that our society has supported and closely co-operated with the
RP research team of Dr Michael Denton, Dr Marion Maw and Robyn
Bridges at Otago University. Now the Otago research team has
made a major genetic breakthrough which will alter the direction
of some of the research into treatments for RP.
Papers from the Otago laboratory, the collaborating German group
of Professor Andreas Gal and a third research team were published
in the same issue of Nature Genetics. The research groups had
each found defects in genes found in the retinal epithelium, a
layer of cells found at the back of the eye. The genes were
RPE65 and RLBP1 and they both play a role in vitamin A pathways
in the retina. Dr Maw and Professor Gal were studying DNA from
20 families in India which had been collected through many years
of dedicated effort by Dr Denton and a number of Indian
collaborators.
Identification of RPE65 as a retinal degeneration gene paved the
way for the recent gene therapy studies. For the first time
vision was restored in an animal model with eyes that approach
the human eye in size. Previously progress had only been made
on mouse models, which does not necessarily transfer to human
sized eyes.
This shows that small research teams in a country like New
Zealand can achieve outstanding results and that identification
of genes is an important first step towards the development of
effective treatments. So, once again I would like to congratulate
Dr Marion Maw and Dr Denton, who nowadays is based mostly in
Pakistan collecting pedigrees of families for DNA analysis by the
Otago University Retinal Degeneration research team.
AUCKLAND STUDENT WINS FIRST PRIZE FOR WORK ON CATARACTS
From Prof Joerg Kistler, School of Biological Sciences, University of
Auckland
Ms Kaa-Sandra Chee, a second year PhD student at Auckland
University School of Biological Sciences has won the overall
National Foundation of Research, Science and Technology First
Prize award, which was presented to her in Christchurch by Nobel
prizewinner Professor Alan MacDiarmid at the end of June.
Miss Chee expects to complete her PhD by mid 2003 and several
publications are likely to arise from her work.
Ms Chee's award winning work is in the area of molecular vision
research, focusing on the mechanisms that the lens has evolved
to maintain transparency. One of the key features that minimizes
light scatter in the lens is that cells are arranged in a highly
ordered fashion, leaving very little space between them.
Furthermore, there are no blood vessels interfering with the path
of light. This poses two problems that the lens has to overcome:
it needs to regulate cell volumes very precisely to not disrupt
the crystalline cell order, and also needs an alternative
mechanism of delivering nutrients to inner portions of the lens.
Indeed, many cataracts start with cortical opacities, which
develop when the cells or the space around them swells
uncontrollably by taking up excess water.
Ms Chee has discovered several transporters which can move
chloride ions across the cell membranes. Because water follows
the ions, these transporters play a major role in keeping cell
volumes precise and thus help maintain lens transparency. Ms
Chee's aim is to identify the molecular isoforms of these
transporters and to learn how they function.
Ms Chee is a member of a larger team that works towards the
common goal to better understand normal lens functions and
determine what goes wrong in cataract. A consortium of three
research groups, led by Professor Joerg Kistler in the School of
Biological Sciences, Dr Donaldson in the School of Medicine, and
Professor Peter Hunter in the School of Engineering,
respectively, has made major progress in defining the molecular
parameters of lens function, and is now in the process of
developing a computer model. This model will be the first of its
kind to help identify new drug targets aimed at preventing
cataract, and also, to predict cataractogenic side-effects of
drugs in clinical use.
In the longer term, therefore, this basic research has the
potential to generate new knowledge that could lead to the
development of novel anticataract therapies. With the increasing
prevalence of cataract associated with longer life expectancies,
and the enormous numbers of cataract surgeries required, new
anticataract strategies are a major health goal world-wide.
INTERESTING FACTS ABOUT CATARACTS
Compiled by June Ombler
Recently I have had several enquiries about cataracts and the
safety of having cataracts removed if you have RP. A search of
my files revealed some interesting information.
What type of cataracts are found in people who have RP?
Research tells us that more than 50% of people with RP develop
cataracts caused by general ageing and exposure to ultra-violet
light. Professor Gislin Dagnelie, Director of Low Vision
Services at Johns Hopkins University School of Medicine in the
U.S.A. says that "Cataracts that are commonly found in
combination with RP affect the rear central part of the lens and
are called posterior subcapsular cataracts or PSC's. Cataracts
caused by sunlight, on the other hand, affect primarily the
centre of the lens and are called nuclear cataracts".
Laser treatment and Cataract extraction:
Several members have expressed concern about possible damaging
effects of laser treatment to remove remnants of the capsule
after cataract removal. Professor Alan Bird of Moorfields
Hospital in London has set out below the facts surrounding this
treatment.
In modern cataract extraction the posterior capsule of the lens
is left intact. This leaves the eye divided into two
compartments. There is overwhelming evidence that leaving the
posterior capsule intact reduces the incidence of complications
and the eye appears to be much healthier. Unfortunately, the
posterior capsule occasionally becomes opaque due to growth of
cells, such that it appears similar to frosted glass and causes
the vision to become blurred. This sequel to cataract extraction
is more common in patients with retinitis pigmentosa (RP) than
in eyes that do not have retinal disease. The problem is
relatively easily resolved. A small hole can be created in the
posterior capsule using a laser. The procedure is undertaken
with drops through a contact lens, takes less than 5 minutes and
does not cause pain. There was some concern that making a hole
in the posterior capsule might be followed by macular oedema, but
experience suggests that if it is undertaken more than three
months after the original cataract surgery, then the risk is
extremely small. From: BRPS News, Winter 1999.
Can Cataract development be slowed?
A question asked of Professor John Marshall at the British RP
Society's AGM in June 2000 was:
Q Is there any medicine that will slow cataract development?
A No, but if it comes to an operation, it is comforting to
note that it is one of the most successful operations
performed, with a success rate of around 98%. Everyone, if
they lived long enough would develop cataracts but the
process can be accelerated by environmental effects, one
being short wavelength light, from blue through to
ultra-violet. Protect your eyes from sunlight by wearing
sunglasses that cut out blue light, for example the orange
tinted "blue bloc" lenses now worn by many members (In the
U.K.)
Dr Dianne Sharp, Retinal specialist from Auckland and member of
the Retina NZ Scientific & Medical Advisory Board comments:
There is an increased chance of developing cataracts as we get
older. The risk of age-related macular degeneration (AMD) also
increases with age and both conditions are affected by exposure
to UV light, while some people have a genetic predisposition.
There is not a specific type of cataract associated with AMD or
macular degeneration. Nuclear sclerosis is a gradual yellowing
of the lens. It may have little effect on vision in the early
stages but be associated with increasing shortsightedness.
Posterior subcapsular lens opacities tend to have a more
significant effect on vision particularly in bright sunlight.
While modern micro-incision surgery has a high success rate,
people with retinal disorders such as RP or AMD and cataract
should be guided by their ophthalmologist to assess their retina
before proceeding with cataract surgery.
OUTCOME OF CATARACT SURGERY IN PATIENTS WITH RETINITIS
PIGMENTOSA
Published in British Journal of Ophthalmology, August, 2001,
85[8]:936-8 By Jackson H, Garway-Heath D, Rosen P, Bird AC, Tuft SJ
Department of Clinical Ophthalmology, Institute of Ophthalmology, Cayton
Street, London, EC1V 9El, UK.
AIM: To determine the visual benefit of cataract extraction in
patients with retinitis pigmentosa and to identify risk factors
for poor outcome.
METHODS: A retrospective analysis was undertaken of a continuous
series of 142 eyes of 89 patients with retinitis pigmentosa
undergoing cataract surgery between 1985 and 1997.
CONCLUSIONS: Cataract surgery for relatively minor lens opacities
is beneficial in patients with retinitis pigmentosa, and most
report subjective improvement of visual symptoms. The incidence
of capsular opacification is high and anterior capsular
contraction may occur. The number of eyes with poor vision due
to macular oedema was unexpectedly low.
RESULTS: Mean age at surgery was 47.5 years (range 24-81 years).
In 100 eyes there was posterior subcapsular lens opacity alone,
37 eyes also had moderate nuclear sclerosis, and five had only
nuclear sclerosis. All patients had central visual fields of <10
degrees.
Overall, mean visual acuity improved from 1.05 (SD 0.38)
preoperatively to 0.63 (SD 0.49) postoperatively on the logMAR
scale.
Significant postoperative capsular opacification occurred in
88/139 eyes (63%) and 45.1% required capsulotomy.
Anterior capsulotomy was undertaken in 5/52 (9.6%) eyes
undergoing phacoemulsification.
Postoperative macular oedema was noted in 20 (14%) eyes. Visual
acuity improved in 109 eyes (77%), was unchanged in 29 eyes
(20.5%), and worsened after surgery in four eyes (2.5%). 86/89
patients reported major improvement of visual function.
WHAT'S IN A COLOUR
By Martine Abel, Auckland Branch member
To see colour, or not to see colour? Well, most people I've
dealt with so far, are of the opinion that, if you can see as
little as I, losing your colour perception should not matter, as
it didn't mean the difference between using a mobility aid or
reading print or not, but this is so untrue!
I could never see much, couldn't even count fingers, but I felt
blessed in a way, for up to 5 years ago, I could distinguish
colours: white, red and black especially, but even yellow, green
and brown at a push. My mother, meaning well and probably not
realising how much this would mean to me later, would let me
build leggo toys and insisted that I make the walls, the cars,
or whatever a specific colour "so that your eyes don't get lazy",
she used to say and I did struggle, but I did as I was told.
And when thinking back, it's always the colour contrasts that
helped me a great deal and that now forms a large part of my
memories: A dark vague spot on a pavement, meaning water; A light
round object on a dark lawn, being a ball; A brownish object on
a white plate, another biscuit left for me; Something shining on
a table, a glass forgotten; A lightish blob on a dark carpet by
my feet, my dearest golden guide dog, Hetty. And this list could
go on and on...
But then, five years ago, Glaucoma snuck up on me like the
proverbial thief in the night, for, as most already know, it is
so hard to catch it in its first stages, the symptoms being:
Night vision loss and perceiving colours very vaguely. So, I
just thought my retina is playing tricks on me. When Glaucoma
was diagnosed at last, I took heaps of medication before going
for an operation to relieve the eye pressure and although my eyes
are totally comfortable now, I've lost that extra spark called
colour forever.
So, is this a warning to all to be cautious on vision symptoms
or just me, reminiscing or even a tribute to my "colourful" past?
Well, maybe all of the above. So, let me ask again: What's in
a colour? A colour by any other name, still brings sweet enough
memories.
About Martine Abel
Martine has Lebers Congenital Amaurosis, a rare hereditary
condition of the Retina where there is extensive loss of sight
in early childhood. Four years ago she contracted Glaucoma as
a secondary eye condition, which took away most of her contrast
and all of her colour perception.
She is an RNZFB Communications Instructor which involves tuition
of Braille, touch typing and basic word processing.
Martine also does Closed Circuit (CCTV) assessments and gives
instruction in all sorts of devices to do with reading
and writing adjustments for the blind and vision impaired.
Photograph: Martine Abel with her dearest golden guide dog, Hetty.
She is a qualified teacher and counsellor and has always enjoyed
studying although it entails a great deal of extra work, taking
adaptive technology and blindness-related matters into account.
Martine is also involved with a few consumer and sports groups
such as Retina NZ (for which she is a Peer Counsellor), ABC NZ,
the Guide Dog Society, Blind Cricket and Blind Indoor bowls.
Martine is in her twenties and has a guide dog called Hetty.
She has been living in NZ for the last five years after
emigrating from South Africa.
As from 1st August 2001, Martine has been appointed for six
months by the RNZFB as the Project Leader for the Braille
Literacy Project
Stage 2.
MILESTONES
BLIND MAN CONQUERS MOUNT EVEREST
By June Ombler
In its 18th June issue Time Magazine devoted its cover photo and
ten pages to an amazing feat by a man blind since he was 13 with
a rare hereditary retinal disease. Erik Weihenmayer, 33, knew
that blindness was inevitable due to his diagnosis of
Retinoschisis, a progressive degenerative blinding disorder of
the retina for which there is no treatment or cure. He accepted
this in his teens and decided to face the challenges that came
his way and see what he could achieve in spite of his blindness.
Erik Weihenmayer climbed Mount Everest, the world's highest
mountain of 8,850 metres. He achieved this in spite of all
predictions that it could not be done by a blind person. Injury
from a fall into a crevasse and suffering altitude sickness
caused him doubts even at Camp One, about facing the unknown
hazards of the dreadfully difficult climb ahead of him. He used
two special poles to feel his way forward and after making ten
trips carrying equipment up the mountain to the higher camps
through the Khumbu Icefall, his climbing speed and confidence
increased and altitude sickness abated.
Erik was no couch potato. He played basketball and competed in
the National Junior Freestyle Wrestling championship in Iowa
while still at school. Needing more challenges, he took up rock
climbing at sixteen and found it was a sport that he could
participate in equally with the sighted. This led him to
mountaineering and he has led teams of climbers up sections of
the El Capitan cliffs in the Yosemite National Park in the USA
and Mount Denali in Alaska. He has also climbed Mount
Kilimanjaro, the highest mountain in Africa, Aconcagua
in Argentina and many other peaks. Another sport he has tried
many times is sky diving.
Erik followed behind sighted climbers using his two poles to feel
his way ahead and listened for voices and the bells on other
climbers' packs to help him with orientation. His climbing team
of nineteen sponsored by the National Federation of the Blind and
others consisted of a documentary filming team who were all
experienced climbers and trusted friends.
The team's first attempt to reach the summit was foiled by bad
weather. On 24th May, in spite of fast running out of time and
terrible weather conditions the team eased their way up the near
vertical mountain to the South summit and across the knifelike
ridge and up the 12 metre Hillary steps. Then on up a snow slope
to triumphantly stand on the summit of the highest mountain in
the world almost 48 years to the day after Sir Edmund Hillary and
Tenzing Norgay were the first people to achieve this feat.
Back home in the USA, his wife Elly and their one-year-old
daughter greeted the news with great relief and joy, awaiting his
homecoming as an American hero, to rate with Helen Keller as an
inspiration and icon to all blind people. With his great
tenacity, Erik Weihenmayer has proved that blind people can
achieve almost anything if they make up their minds to do so.
OTAGO/SOUTHLAND BRANCH CHAIRPERSON PUBLISHES HER FIRST BOOK
Helen Adams, Chairperson of Retina NZ's Otago/Southland Branch
recently jointly published her first book, "Vi Fraser's
Country", the life and times of her mother, who was born in 1904
and died in 1999. Spanning the 20th century, it tells of the
life of a farmer's wife who lived in the high country backblocks
in the Hakataramea Valley beyond Kurow, to Weston, Five Forks and
Oamaru in the South Island.
Vi Fraser was well-known in North Otago for her short stories and
poems which she wrote for magazines, newspapers and the radio.
In her later years she won many prizes in the Charles Croot
Creative Writing competition and for her poetry in the Third Age
Poetry competitions.
Written notes and tapes made by her mother and some genealogical
research by her husband Geoff enabled Helen Adams to put the book
together as an autobiography of her mother. Published by
themselves, the book gives both an interesting life story and a
particularly comprehensive picture of the life of a farmer's wife
living in the high country backblocks in the days before
electricity, and when there were very few motor cars.
FORTHCOMING EVENTS
Auckland Branch News:
Auckland Branch members will be manning a booth at the "No
Nonsense Eye Sense" Expo to be held on Saturday, 22nd September
from 10.00 am to 4.30 pm in the Lordship Lounge, Alexandra Park
Function Centre, Alexandra Park Raceway, corner of Greenlane and
Manukau Road. The function centre is located inside the grounds
of the Alexandra Park Raceway.
Retina New Zealand will have available concise and easy to read
information which will help people "hope and cope" with their
retinal or allied eye disorder. Retina NZ representatives from
the Auckland Branch will be in attendance and happy to answer a
range of questions such as:
* Where do I get clinical information on my condition?
* Is there any research into treating my condition?
* Are there people with similar conditions to my own who I can talk to?
* What should I do about my mother or friend who appear to be losing their sight?
Retina New Zealand is proud of its programmes that deliver peer
support services and clinical and research information
dissemination services to a steadily growing number of New
Zealander's. So why not come and find out who your Auckland
Branch are and whether Retina NZ can assist you or your partner,
friend or relative.
Organised by the Royal NZ Foundation for the Blind and Retina NZ,
there will be around 15 to 20 exhibits staffed by optometrists,
sunglasses firms and interest groups such as Retina NZ, and the
Eye Bank. There will be expert speakers on eye conditions, a
variety of free eye tests, glasses frame advice and free
information kits. It should be huge!! The Expo is targeted at
the over 50 age group but everybody is welcome. Make sure you
go with all your older relatives and friends. There is no charge
to enter.
How to get there:
By car:
* If travelling north on the Southern Motorway, exit at
Greenlane.
At Greenlane Interchange turn left onto Greenlane Road past
Greenlane Hospital to Alexandra Park Raceway on the right to the
main gates of Auckland Trotting Club and Alexandra Park Function
Centre. Take Gate B or C to drive into the complex.
* If travelling South on the Southern Motorway, take Greenlane
exit and turn right into Greenlane Road past Greenlane Hospital.
On the right is Alexandra Park Raceway taking you to the main
gates of Auckland Trotting Club. Take Gate B or C to drive to
the function centre.
Parking:
Disabled car parks are clearly marked outside Centennial and
Members stands and other areas. Ample ordinary car parks
available.
Bus:
Central Auckland routes 304, 305, 312 and 328 get you to within
300 metres. Consult the journey planner on
http://www.rideline.co.nz
Train:
From Central Auckland take Tranz Metro train route STH to Remuera
Stn and walk or taxi 2028 metres to venue. Refer to journey
planner on http://www.rideline.co.nz
For more information, please contact Fraser Alexander on (09)
3556-914 or (025) 840 937 or e-mail Fraser on
falexander@rnzfb.org.nz
Wellington Branch News:
This year Wellington Branch will be hosting the Society's Annual
General Meeting on World Retina Day, Saturday 29th September.
The meeting will be held in the premises of the Royal NZ
Foundation for the Blind, 121 Adelaide Road, Wellington.
Please come with your family and particularly your older
relatives as the Society is launching its latest booklet "About
Macular Degeneration - a New Zealand Guide to Macular
Degeneration", which includes information about Age-related
Macular Degeneration.
The Annual General Meeting will begin at 10.15 am and there will
be a break for lunch provided by Wellington Branch from 12.45 to
1.45 pm. After lunch Dr Marion Maw, Chair of the Retina
Scientific & Medical Advisory Board will lead a discussion on
Genetics.
Following the afternoon session there will be a wine and cheese
"Reaching Out" function to which everyone is invited.
This is a draft of the day at the moment but the final agenda
will be sent to you nearer the time with the remits to be
discussed, Proxy forms and C.V.'s of candidates for the President
for the following two year term.
Please write this date in your diary to reserve the day and be
sure to come. Wellington Branch and the Retina Executive look
forward to meeting you there!
CHANGE OF RETINA INTERNATIONAL WORLD WIDE WEB ADDRESS
We would like to inform you that the International Retinitis
Pigmentosa Association (IRPA) was renamed to become Retina
International.
This Name change was reflected by listing our webpage as
http://www.retina-international.org and
http://www.retina-international.com on the world wide web.
In the meantime the www.irpa.org domain has expired and was taken
over by a domain name broker. He unfortunately links it currently
to some sites which are not really related to our cause.
May we kindly ask, if you could update your link (www.irpa.org)
to point to our new web address
http://www.retina-international.org
Philipp Schlaeppi, Retina Suisse
Email : webmaster@retina-international.org
DO YOU NEED HELP OR ADVICE?
The Retina NZ Peer Support programme is a free and
confidential service, operating nationwide. To make contact,
telephone 0800 243 33 33, press 1 for General enquiries and
then ask the call centre operator to put you in touch with a
Peer Supporter in your area.
Auckland Genetic Hotline
(Ask for Dr Julie McGaughran) 0800 476 123
Wellington Genetic Hotline 0508 364 436
Christchurch Genetic Hotline 0508 364 436
(South Island callers ask for Dr Caroline
Lintott)
Janet Palmer, National Secretary
P.O. Box 27-177, Wellington
Phone: (04) 380-2160.
Fax: (04) 389-5254.
Email : retinanz@ihug.co.nz
Website address: www.retina.org.nz
(Please note a recent change of phone number for the RNZFB in
Wellington as listed above). The fax number remains the same).
CLOSING DATE FOR RECEIPT OF ARTICLES FOR THE NEXT ISSUE IS
FRIDAY 9 NOVEMBER 2001.
Anthony Haas
|